Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + BEAM + AHSCT in CD20+ NHL
NCT00080886Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- May 2002
- Primary completion
- Nov 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in B-cell non-Hodgkin lymphoma, sponsored by University of Nebraska. Primary endpoint: Levels of soluble CD20 antigen. Started May 2002; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00080886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080886.